Wang Y, Wang B, Zhou L, Wan Y, Zheng Y, Zhou L
Am J Cancer Res. 2025; 14(12):5680-5696.
PMID: 39803652
PMC: 11711526.
DOI: 10.62347/RLVZ6860.
Skoulidis F, Araujo H, Do M, Qian Y, Sun X, Cobo A
Nature. 2024; 635(8038):462-471.
PMID: 39385035
PMC: 11560846.
DOI: 10.1038/s41586-024-07943-7.
Liang Y, Maeda O, Kondo C, Nishida K, Ando Y
PLoS One. 2024; 19(7):e0307580.
PMID: 39037971
PMC: 11262633.
DOI: 10.1371/journal.pone.0307580.
Su H, Yang Y, Li C, Li J, Lv H, Jia X
J Cancer. 2024; 15(12):4020-4039.
PMID: 38911387
PMC: 11190773.
DOI: 10.7150/jca.91277.
Lou Y, Zou L, Shen Z, Zheng J, Lin Y, Zhang Z
Front Pharmacol. 2024; 15:1396713.
PMID: 38863982
PMC: 11165180.
DOI: 10.3389/fphar.2024.1396713.
Energy metabolism as the hub of advanced non-small cell lung cancer management: a comprehensive view in the framework of predictive, preventive, and personalized medicine.
Bajinka O, Ouedraogo S, Golubnitschaja O, Li N, Zhan X
EPMA J. 2024; 15(2):289-319.
PMID: 38841622
PMC: 11147999.
DOI: 10.1007/s13167-024-00357-5.
Prevalence and Associations of Co-occurrence of Mutations and Chromosome 3q26 Amplification in Lung Cancer.
Liu J, Liu S, Li D, Li H, Zhang F
Glob Med Genet. 2024; 11(2):150-158.
PMID: 38628662
PMC: 11018393.
DOI: 10.1055/s-0044-1786004.
Research Progress of Plant-Derived Natural Products against Drug-Resistant Cancer.
Liu W, Wang Y, Xia L, Li J
Nutrients. 2024; 16(6).
PMID: 38542707
PMC: 10975298.
DOI: 10.3390/nu16060797.
-Mutant Lung Cancers Weaken Anti-Tumor Immunity and Promote an M2-like Macrophage Phenotype.
Occhiuto C, Liby K
Int J Mol Sci. 2024; 25(6).
PMID: 38542481
PMC: 10970780.
DOI: 10.3390/ijms25063510.
Glutamine antagonist DRP-104 suppresses tumor growth and enhances response to checkpoint blockade in mutant lung cancer.
Pillai R, LeBoeuf S, Hao Y, New C, Blum J, Rashidfarrokhi A
Sci Adv. 2024; 10(13):eadm9859.
PMID: 38536921
PMC: 10971495.
DOI: 10.1126/sciadv.adm9859.
Outcomes in patients treated with frontline immune checkpoint inhibition (ICI) for advanced NSCLC with KRAS mutations and STK11/KEAP1 comutations across PD-L1 levels.
Sun L, Handorf E, Zhou Y, Borghaei H, Aggarwal C, Bauman J
Lung Cancer. 2024; 190:107510.
PMID: 38432028
PMC: 11194721.
DOI: 10.1016/j.lungcan.2024.107510.
Combining Genomic Biomarkers to Guide Immunotherapy in Non-Small Cell Lung Cancer.
van de Haar J, Mankor J, Hummelink K, Monkhorst K, Smit E, Wessels L
Clin Cancer Res. 2024; 30(7):1307-1318.
PMID: 38300729
PMC: 10982639.
DOI: 10.1158/1078-0432.CCR-23-4027.
Regulation of antioxidants in cancer.
Hecht F, Zocchi M, Alimohammadi F, Harris I
Mol Cell. 2023; 84(1):23-33.
PMID: 38029751
PMC: 10843710.
DOI: 10.1016/j.molcel.2023.11.001.
Whole brain radiation therapy resulting in radionecrosis: a possible link with radiosensitising chemoimmunotherapy.
Ngu S, Werner C, D Amico R, Wernicke A
BMJ Case Rep. 2023; 16(11).
PMID: 38016763
PMC: 10685978.
DOI: 10.1136/bcr-2023-256758.
Nestin overexpression reduces the sensitivity of gastric cancer cells to trastuzumab.
Wei Y, Zhu J, Wu J, Yu S, Li W, Zhu M
J Gastrointest Oncol. 2023; 14(4):1694-1706.
PMID: 37720426
PMC: 10502550.
DOI: 10.21037/jgo-22-1048.
AMPK-Mediated Phosphorylation of Nrf2 at S374/S408/S433 Favors Its βTrCP2-Mediated Degradation in KEAP1-Deficient Cells.
Petsouki E, Ender S, Sosa Cabrera S, Heiss E
Antioxidants (Basel). 2023; 12(8).
PMID: 37627580
PMC: 10451539.
DOI: 10.3390/antiox12081586.
Cancer Cell-Intrinsic Alterations Associated with an Immunosuppressive Tumor Microenvironment and Resistance to Immunotherapy in Lung Cancer.
Otegui N, Houry M, Arozarena I, Serrano D, Redin E, Exposito F
Cancers (Basel). 2023; 15(12).
PMID: 37370686
PMC: 10295869.
DOI: 10.3390/cancers15123076.
Flow Cytometry Identification of Cell Compartments in the Murine Brain.
Moffet J, Moore Z, Oliver S, Towers T, Jenkins M, Freytag S
Methods Mol Biol. 2023; 2691:185-198.
PMID: 37355546
DOI: 10.1007/978-1-0716-3331-1_14.
Distinct Nrf2 Signaling Thresholds Mediate Lung Tumor Initiation and Progression.
DeBlasi J, Falzone A, Caldwell S, Prieto-Farigua N, Prigge J, Schmidt E
Cancer Res. 2023; 83(12):1953-1967.
PMID: 37062029
PMC: 10267679.
DOI: 10.1158/0008-5472.CAN-22-3848.
The Multi-Faceted Consequences of NRF2 Activation throughout Carcinogenesis.
Occhiuto C, Moerland J, Leal A, Gallo K, Liby K
Mol Cells. 2023; 46(3):176-186.
PMID: 36994476
PMC: 10070161.
DOI: 10.14348/molcells.2023.2191.